Study: Remdesivir at Covid-19 effective
The anti-viral drug Remdesivir accelerated in patients with COVID-19, the recovery time and lowered cases, the number of death. This emerges from a randomized control study, conducted among over 1000 patients in different countries.
Topics Of Special Coronavirus
More recent contributions to SARS-CoV-2, and Covid-19 can be found in the special Coronavirus on aponet.de.
Patients who were suffering from the novel Coronavirus SARS-CoV-2, and ten days Remdesivir had received, were dismissed after an average of eleven days out of the hospital. In the control group, where only a Placebo had been administered, it took an average of 15 days. With Remdesivir it came to cases, 7.1 per cent of the patients death, in the Placebo group died of 11.9 percent. Especially seriously Ill, the additional oxygen required, benefited from the treatment, as the doctors in the leading medical journal "The New England Journal of Medicine" signs.
The result is slightly below the statistical reliability threshold, which means that it may be due to the random and by results of a larger sample underpinning needs to be. In addition, could not be prevented by the drug, all of the deaths. The researchers conclude: "Given the high mortality despite the use of Remdesivir, it is not clear that the treatment with an antiviral drug alone is not enough probably." Nevertheless, Dr. Anthony Fauci, Director of the US government Agency the National Institute of Allergy and Infectious Diseases came to the conclusion, Remdesivir have a "unique, significant and positive effect on the reduction of the time to Genesung".
Antimalarials chloroquine enttäareas of scrub
In contrast, the active ingredients disappointed chloroquine and hydroxychloroquine, to which also many of the hopes for the Covid-19-treatment rest. A study of almost 100,000 patients, the "The Lancet" published, came to the sobering results: When different preparations containing these substances have a significantly higher mortality and significantly more life-threatening heart were observed arrhythmias than patients who were not treated with it. Based on the results, the managers have paused in the study to check the data on the safety of this therapy carefully. Covid-19 seems to be a special case, because in the usual areas of application of these preparations, such as Malaria or autoimmune diseases they apply to patients, as safe.
Sources: DOI 10.1056/NEJMoa2007764 DOI 10.1016/S0140-6736(20)31180-6
An Overview of all the messages you get on aponet.de current.